Diamond Biotechnology Co., Ltd (6815) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Diamond Biotechnology Co., Ltd stock TWD 3.71, price TWD 19.00, that is 80.5% below the price, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 16.25 TWD – 109.72 TWD · fair‑value band 2.45 TWD – 4.64 TWD · the 19.00 TWD price screens above the 3.71 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Diamond Biotechnology Co. in your weekly email
Every Wednesday you see whether Diamond Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment.
Show moreShow less
Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.
Stock analysis
Diamond Biotechnology Co., Ltd (6815) currently trades at 19.00 TWD, while our model-based Fair Value estimate is 3.71 TWD, 80% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 2.45 TWD (bear) to 4.64 TWD (bull), the price of 19.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Diamond Biotechnology Co., Ltd reported revenue of 501M TWD in FY2025 versus 395M TWD in FY2021, a compound +6.1%/yr. Reported net income was −70.3M TWD in FY2025.
Key figures
Market cap 750M TWD (≈ $22.9M) Micro · P/S ratio 1.76 · EPS (TTM) −1.21 TWD · Net margin −10.2% · Return on equity −8.0% · Return on assets (EBIT) 5.3% (5-year average) · Operating margin 15.9% · Revenue (TTM) 465M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −80%, 6815 screens richer than that median.
Fair Value models
Bear2.45 TWDFair Value 3.71 TWDBull4.64 TWD
Price 19.00 TWD · Downside -80.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)2.88 TWD4.37 TWD5.46 TWD54
All 1 models by family
Asset-Based
NCAV (Graham)2.88 TWD4.37 TWD5.46 TWD54
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−34.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.9% (2020) → −14.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Diamond Biotechnology Co., Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−80.5% · Bottom 25%
Profitability
Return on assets−8.1% · Below median
Net margin (12 months)−10.2% · Bottom 25%
Operating margin (12 months)15.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−11.6% · Bottom 25%
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.38× · Cheaper than median
P/S (12 months)1.62× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 36
PAST (return on equity)0· sector 17
HEALTH (low debt)84· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Diamond Biotechnology Co., Ltd (6815) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 3.71 TWD versus a price of 19.00 TWD, about 80% lower (overvalued).
What is the fair value of 6815?
Our model-based fair value for Diamond Biotechnology Co., Ltd is 3.71 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 19.00 TWD.
What is the quality score of 6815?
Diamond Biotechnology Co., Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diamond Biotechnology Co., Ltd (6815)?
Our model-based price target is the fair value of 3.71 TWD (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 2.45 TWD, optimistic scenario 4.64 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Diamond Biotechnology Co., Ltd stock forecast for 2026?
Our models put fair value at 3.71 TWD, about 80% lower versus a price of 19.00 TWD (overvalued). Cautious scenario 2.45 TWD, optimistic scenario 4.64 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Diamond Biotechnology Co., Ltd (6815)?
Diamond Biotechnology Co., Ltd reported trailing-twelve-month revenue of about 465M TWD (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Diamond Biotechnology Co., Ltd (6815)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diamond Biotechnology Co., Ltd it is 3.71 TWD per share (as of Nov 3, 2026), against a price of 19.00 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Diamond Biotechnology Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6815 trades above its calculated fair value: price 19.00 TWD, fair value 3.71 TWD, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6815?
No. The price is what the market pays today (19.00 TWD); the fair value is what the company's own numbers justify (3.71 TWD). For Diamond Biotechnology Co., Ltd the two are 15.29 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Diamond Biotechnology Co., Ltd worth?
The market values Diamond Biotechnology Co., Ltd at about 750M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 19.00 TWD; our models calculate a fair value of 3.71 TWD per share.
What do the bullish and bearish scenarios say about 6815?
Our models span a range for Diamond Biotechnology Co., Ltd: cautious scenario 2.45 TWD, base 3.71 TWD, optimistic 4.64 TWD per share (as of Nov 3, 2026, price 19.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Diamond Biotechnology Co., Ltd (6815)?
Balance-sheet figures for Diamond Biotechnology Co., Ltd (as of Nov 3, 2026): return on equity −8.0%, debt of 0.32 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 6815 from its 52-week high?
Diamond Biotechnology Co., Ltd trades at 19.00 TWD, about 74% below its 52-week high of 71.90 TWD and at the low of 19.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3.71 TWD is for.
Which stocks are comparable to Diamond Biotechnology Co., Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diamond Biotechnology Co., Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 19.00 TWD, calculated fair value 3.71 TWD (−80%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6815 calculated?
We run Diamond Biotechnology Co., Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 3.71 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Diamond Biotechnology Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diamond Biotechnology Co., Ltd (6815)?
The closing price on Nov 6, 2026 was 19.00 TWD. Our model-based fair value is 3.71 TWD, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diamond Biotechnology Co., Ltd right now?
The price sits above even our optimistic bull case (4.64 TWD). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.45 TWD to 4.64 TWD) leaves room in how you read the outcome.
Key figures of Diamond Biotechnology Co., Ltd
How large is the market capitalisation of Diamond Biotechnology Co., Ltd (6815)?
The market capitalisation of Diamond Biotechnology Co., Ltd is 750M TWD (≈ $22.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diamond Biotechnology Co., Ltd (6815)?
The price-to-sales ratio of Diamond Biotechnology Co., Ltd is 1.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Diamond Biotechnology Co., Ltd (6815)?
Earnings per share at Diamond Biotechnology Co., Ltd are −1.21 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Diamond Biotechnology Co., Ltd (6815)?
The net margin of Diamond Biotechnology Co., Ltd is −10.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diamond Biotechnology Co., Ltd (6815)?
The return on equity (ROE) of Diamond Biotechnology Co., Ltd is −8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diamond Biotechnology Co., Ltd (6815)?
On an EBIT basis the return on assets of Diamond Biotechnology Co., Ltd is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diamond Biotechnology Co., Ltd (6815)?
The operating margin of Diamond Biotechnology Co., Ltd is 15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diamond Biotechnology Co., Ltd (6815)?
Revenue at Diamond Biotechnology Co., Ltd is growing −11.6% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diamond Biotechnology Co., Ltd (6815)?
Earnings per share at Diamond Biotechnology Co., Ltd are growing +191% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Diamond Biotechnology Co., Ltd (6815) generate?
The free cash flow of Diamond Biotechnology Co., Ltd is −3.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Diamond Biotechnology Co., Ltd (6815) carry?
The net debt of Diamond Biotechnology Co., Ltd is 83.2M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Diamond Biotechnology Co., Ltd in the live analysis
One click puts Diamond Biotechnology Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026